Severe pneumonia?AECOPD
Conditions
Interventions
Low dose group:Base treatment+Lianhua Qingke Tablets, 4 tablets/time, 3 times/day
High dose group:Base treatment+Lianhua Qingke Tablets, 8 tablets/time, 3 times/day
Control group:Base treatment
Sponsors
The Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Met diagnostic criteria for severe pneumonia; 2.18 years <= age <= 80 years; 3. Acute onset of severe community-acquired pneumonia or chronic obstructive pulmonary disease according to the source of infection and different etiological classification; 4. Diagnosis of severe pneumonia within 48h; 5. The patient or family members were aware of the content of the study and voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with severe cardiac dysfunction and hepatic and renal failure; 2. Patient expected survival less than 14 days due to underlying disease, such as poor control of malignancy, cardiac arrest within 30 days prior, etc; 3. Patients with serious mental illness; 4. Those who are pregnant or preparing for pregnancy, or are unable to take effective measures of contraception; 5. Allergy to the active ingredients of the test drug or to their excipients; 6. Had participated in a clinical intervention trial within nearly 3 months; 7. Subjects who, in the opinion of the attending physician, would not be eligible for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| APACHE II scale score change values and rate of change; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total length of ICU stay;On treatment mortality in patients with severe pneumonia;Degree of chest X-ray changes;Sputum: viscosity analysis of sputum; Extracellular trapping of neutrophils and inflammatory factors;Detection of blood samples: analysis of inflammatory factors, inflammatory cell typing and proportions (macrophages, neutrophils, epithelial cells);Alveolar lavage fluid: inflammatory cell typing and proportions (macrophages, neutrophils, epithelial cells), analysis of inflammatory cytokines, mucin (MUC5AC) content analysis;Stool: 16S sequencing, metagenomic sequencing;Airway mucosa: biopsy forceps were taken for pathological analysis of airway mucosal cell composition and proportion; Tracheal brushings were obtained for epithelial / immune cell typing and cilia length and ciliary beat frequency analysis from ciliated cells; | — |
Countries
China
Contacts
Public ContactYadong Yuan
The Second Hospital of Hebei Medical University
Outcome results
None listed